Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 4.3% year on year to $149.8 million. On the other hand, the company’s full-year revenue guidance of $615 million at the midpoint came in 1.6% below analysts’ estimates. Its GAAP loss of $0.21 per share was significantly below analysts’ consensus estimates.
Global professional services company Jacobs Solutions (NYSE:J) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 2.2% year on year to $2.91 billion. Its non-GAAP profit of $1.48 per share was 6.9% above analysts’ consensus estimates.
Health insurance company Clover Health (NASDAQ:CLOV) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 33.3% year on year to $462.3 million. Its GAAP loss of $0 per share was significantly above analysts’ consensus estimates.
Higher education company Grand Canyon Education (NASDAQ:LOPE) announced better-than-expected revenue in Q1 CY2025, with sales up 5.3% year on year to $289.3 million. The company expects next quarter’s revenue to be around $240.3 million, close to analysts’ estimates. Its GAAP profit of $2.52 per share was 2.9% above analysts’ consensus estimates.
Senior living provider The Pennant Group (NASDAQ:PNTG) announced better-than-expected revenue in Q1 CY2025, with sales up 33.7% year on year to $209.8 million. Its non-GAAP profit of $0.27 per share was 13.7% above analysts’ consensus estimates.
Aerospace and defense company Cadre (NYSE:CDRE) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 5.6% year on year to $130.1 million. The company’s full-year revenue guidance of $633 million at the midpoint came in 5.8% above analysts’ estimates. Its GAAP profit of $0.23 per share was 91.7% above analysts’ consensus estimates.
Residential swimming pool manufacturer Latham (NASDAQ:SWIM) met Wall Street’s revenue expectations in Q1 CY2025, but sales were flat year on year at $111.4 million. The company’s full-year revenue guidance of $550 million at the midpoint came in 2.5% above analysts’ estimates. Its GAAP loss of $0.05 per share was 38.1% above analysts’ consensus estimates.
Biotech company Sarepta Therapeutics (NASDAQ:SRPT) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 80.2% year on year to $744.9 million. Its non-GAAP loss of $3.42 per share was significantly below analysts’ consensus estimates.
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $897.8 million. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $4.28 billion at the midpoint. Its non-GAAP profit of $1.68 per share was 63.9% below analysts’ consensus estimates.
Genetic testing company Myriad Genetics (NASDAQ:MYGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.1% year on year to $195.9 million. The company’s full-year revenue guidance of $815 million at the midpoint came in 3.7% below analysts’ estimates. Its non-GAAP loss of $0.03 per share was $0.02 above analysts’ consensus estimates.
Global electronics contract manufacturer Kimball Electronics (NYSE:KE) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, but sales fell by 11.9% year on year to $374.6 million. The company expects the full year’s revenue to be around $1.42 billion, close to analysts’ estimates. Its non-GAAP profit of $0.27 per share was 42.1% above analysts’ consensus estimates.
Luxury hotels and casino operator Wynn Resorts (NASDAQ:WYNN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 8.7% year on year to $1.7 billion. Its non-GAAP profit of $1.07 per share was 14% below analysts’ consensus estimates.
Outdoor living products manufacturer AZEK Company (NYSE:AZEK) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 8.1% year on year to $452.2 million. On the other hand, the company’s full-year revenue guidance of $1.54 billion at the midpoint came in 0.9% below analysts’ estimates. Its non-GAAP profit of $0.45 per share was 2.9% above analysts’ consensus estimates.
Wellness products company Nature’s Sunshine (NASDAQ:NATR) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 2% year on year to $113.2 million. The company expects the full year’s revenue to be around $457.5 million, close to analysts’ estimates. Its GAAP profit of $0.25 per share was 51.5% above analysts’ consensus estimates.
Uniform rental provider Vestis Corporation (NYSE:VSTS) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 5.7% year on year to $665.2 million. Next quarter’s revenue guidance of $678 million underwhelmed, coming in 4.8% below analysts’ estimates. Its non-GAAP loss of $0.05 per share was significantly below analysts’ consensus estimates.
Lift truck and material handling solutions manufacturer Hyster-Yale Materials Handling (NYSE:HY) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 13.8% year on year to $910.4 million. Its non-GAAP profit of $0.49 per share was in line with analysts’ consensus estimates.
Market indexes regained all of their losses since the president’s “Liberation Day” tariff announcement one month ago, culminating in an historic +10% 9-day rally for the S&P 500.
Technology real estate company Opendoor (NASDAQ:OPEN) announced better-than-expected revenue in Q1 CY2025, but sales fell by 2.4% year on year to $1.15 billion. Guidance for next quarter’s revenue was optimistic at $1.49 billion at the midpoint, 2.5% above analysts’ estimates. Its GAAP loss of $0.12 per share was 7.7% above analysts’ consensus estimates.
Healthcare services company Agilon Health (NYSE:AGL) announced better-than-expected revenue in Q1 CY2025, but sales fell by 4.5% year on year to $1.53 billion. On the other hand, next quarter’s revenue guidance of $1.47 billion was less impressive, coming in 0.5% below analysts’ estimates. Its GAAP loss of $0 per share was in line with analysts’ consensus estimates.
